» Articles » PMID: 18218085

The Combined Immunodetection of AP-2alpha and YY1 Transcription Factors is Associated with ERBB2 Gene Overexpression in Primary Breast Tumors

Overview
Specialty Oncology
Date 2008 Jan 26
PMID 18218085
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Overexpression of the ERBB2 oncogene is observed in about 20% of human breast tumors and is the consequence of increased transcription rates frequently associated with gene amplification. Several studies have shown a link between activator protein 2 (AP-2) transcription factors and ERBB2 gene expression in breast cancer cell lines. Moreover, the Yin Yang 1 (YY1) transcription factor has been shown to stimulate AP-2 transcriptional activity on the ERBB2 promoter in vitro. In this report, we examined the relationships between ERBB2, AP-2alpha, and YY1 both in breast cancer tissue specimens and in a mammary cancer cell line.

Methods: ERBB2, AP-2alpha, and YY1 protein levels were analyzed by immunohistochemistry in a panel of 55 primary breast tumors. ERBB2 gene amplification status was determined by fluorescent in situ hybridization. Correlations were evaluated by a chi2 test at a p value of less than 0.05. The functional role of AP-2alpha and YY1 on ERBB2 gene expression was analyzed by small interfering RNA (siRNA) transfection in the BT-474 mammary cancer cell line followed by real-time reverse transcription-polymerase chain reaction and Western blotting.

Results: We observed a statistically significant correlation between ERBB2 and AP-2alpha levels in the tumors (p < 0.01). Moreover, associations were found between ERBB2 protein level and the combined high expression of AP-2alpha and YY1 (p < 0.02) as well as between the expression of AP-2alpha and YY1 (p < 0.001). Furthermore, the levels of both AP-2alpha and YY1 proteins were inversely correlated to ERBB2 gene amplification status in the tumors (p < 0.01). Transfection of siRNAs targeting AP-2alpha and AP-2gamma mRNAs in the BT-474 breast cancer cell line repressed the expression of the endogenous ERBB2 gene at both the mRNA and protein levels. Moreover, the additional transfection of an siRNA directed against the YY1 transcript further reduced the ERBB2 protein level, suggesting that AP-2 and YY1 transcription factors cooperate to stimulate the transcription of the ERBB2 gene.

Conclusion: This study highlights the role of both AP-2alpha and YY1 transcription factors in ERBB2 oncogene overexpression in breast tumors. Our results also suggest that high ERBB2 expression may result either from gene amplification or from increased transcription factor levels.

Citing Articles

Effects of methylation and transcription factor YY1 on ID2 expression in non-small cell lung carcinoma cells.

Tseng Y, Chou W, Liu W, Dung Z, Lin C, Hsieh C Am J Cancer Res. 2024; 14(5):2424-2438.

PMID: 38859862 PMC: 11162666. DOI: 10.62347/KXKL1421.


Clinical Potential of YY1-Hypoxia Axis for Vascular Normalization and to Improve Immunotherapy.

Meo C, de Nigris F Cancers (Basel). 2024; 16(3).

PMID: 38339244 PMC: 10854702. DOI: 10.3390/cancers16030491.


Cross-Talks between RKIP and YY1 through a Multilevel Bioinformatics Pan-Cancer Analysis.

Baritaki S, Zaravinos A Cancers (Basel). 2023; 15(20).

PMID: 37894300 PMC: 10605344. DOI: 10.3390/cancers15204932.


Role of YY1 in the Regulation of Anti-Apoptotic Gene Products in Drug-Resistant Cancer Cells.

Jung M, Bui I, Bonavida B Cancers (Basel). 2023; 15(17).

PMID: 37686541 PMC: 10486809. DOI: 10.3390/cancers15174267.


Identification of cell subpopulations associated with disease phenotypes from scRNA-seq data using PACSI.

Liu C, Zhang Y, Gao X, Wang G BMC Biol. 2023; 21(1):159.

PMID: 37468850 PMC: 10354926. DOI: 10.1186/s12915-023-01658-3.


References
1.
Begon D, Delacroix L, Vernimmen D, Jackers P, Winkler R . Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J Biol Chem. 2005; 280(26):24428-34. DOI: 10.1074/jbc.M503790200. View

2.
Gee J, Robertson J, Ellis I, Nicholson R, Hurst H . Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol. 2000; 189(4):514-20. DOI: 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9. View

3.
Kannan P, Tainsky M . Coactivator PC4 mediates AP-2 transcriptional activity and suppresses ras-induced transformation dependent on AP-2 transcriptional interference. Mol Cell Biol. 1998; 19(1):899-908. PMC: 83947. DOI: 10.1128/MCB.19.1.899. View

4.
Creaser P, DArgenio D, Williams T . Comparative and functional analysis of the AP2 promoter indicates that conserved octamer and initiator elements are critical for activity. Nucleic Acids Res. 1996; 24(13):2597-605. PMC: 145978. DOI: 10.1093/nar/24.13.2597. View

5.
Delacroix L, Begon D, Chatel G, Jackers P, Winkler R . Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells. DNA Cell Biol. 2005; 24(9):582-94. DOI: 10.1089/dna.2005.24.582. View